TY - JOUR
T1 - Treatment of Candida nail infection with terbinafine
AU - Segal, Rina
AU - Kritzman, Aharon
AU - Cividalli, Lia
AU - Samra, Zmira
AU - David, Michael
N1 - Funding Information:
From the Departments of Dermatology a and Microbiology? Beilinson Medical Centre, Petah Tikva, and the Sackler Faculty of Medicine, Tel-Aviv University. Supported by a grant from Sandoz Pharma Ltd, Basel, Switzerland. Reprint requests: Rina Segal, Department of Dermatology, Beilinson Medical Center, Petah Tikva, 49100, Israel. *Abramson C, Berlin S. Increased incidence of nondermatophyte fil-amentous fungi in skin and toenail infections. Abstracts of the Inter-national Summit on Cutaneous Antifungal Therapy, Boston, 1994. Copyright © 1996 by the American Academy of Dermatology, Inc. 0190-9622/96 $5.00 + 0 16/1/74900
PY - 1996/12
Y1 - 1996/12
N2 - Background: Terbinafine is a highly potent drug against dermatophytes. Data regarding its effectiveness against Candida species are few and variable. Objective: Our purpose was to evaluate the efficacy and safety of oral terbinafine in patients with Candida nail infection. Methods: In an open-label uncontrolled study, 20 patients completed 16 weeks of treatment with terbinafine, 250 mg/day, and an additional 8 weeks with placebo. Efficacy was assessed clinically and mycologically at weeks 0 (baseline), 4, 8, 16, 24, 36, and 48. Routine laboratory studies were performed at baseline and weeks 4, 8, and 16. Results: At the end of the trial 60% of target nails were cured clinically and mycologically; in 10% there was mycologic cure with residual clinical signs, in 25% a moderate improvement (>50%), and failure in only 5% (one patient). Most nails were infected by Candida parapsilosis. Two of 28 patients showed mild reversible elevation of liver enzymes 1 month after initiation of terbinafine treatment. Conclusion: The administration of terbinafine lot 16 weeks is effective in the treatment of Candida nail infection. Liver enzyme values should be determined during the first month of treatment.
AB - Background: Terbinafine is a highly potent drug against dermatophytes. Data regarding its effectiveness against Candida species are few and variable. Objective: Our purpose was to evaluate the efficacy and safety of oral terbinafine in patients with Candida nail infection. Methods: In an open-label uncontrolled study, 20 patients completed 16 weeks of treatment with terbinafine, 250 mg/day, and an additional 8 weeks with placebo. Efficacy was assessed clinically and mycologically at weeks 0 (baseline), 4, 8, 16, 24, 36, and 48. Routine laboratory studies were performed at baseline and weeks 4, 8, and 16. Results: At the end of the trial 60% of target nails were cured clinically and mycologically; in 10% there was mycologic cure with residual clinical signs, in 25% a moderate improvement (>50%), and failure in only 5% (one patient). Most nails were infected by Candida parapsilosis. Two of 28 patients showed mild reversible elevation of liver enzymes 1 month after initiation of terbinafine treatment. Conclusion: The administration of terbinafine lot 16 weeks is effective in the treatment of Candida nail infection. Liver enzyme values should be determined during the first month of treatment.
UR - http://www.scopus.com/inward/record.url?scp=0029752998&partnerID=8YFLogxK
U2 - 10.1016/S0190-9622(96)90120-6
DO - 10.1016/S0190-9622(96)90120-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0029752998
SN - 0190-9622
VL - 35
SP - 958
EP - 961
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 6
ER -